Overview Bioequivalence - Duodart Against Avodart & Omnic Status: Completed Trial end date: 2012-12-05 Target enrollment: Participant gender: Summary Open-label, randomized, single dose, two-treatment, two-way crossover study Phase: Phase 1 Details Lead Sponsor: GlaxoSmithKlineTreatments: DutasterideTamsulosin